BioNexus Gene Lab
BGLC
4 hedge funds and large institutions have $70.7K invested in BioNexus Gene Lab in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
26% more capital invested
Capital invested by funds: $55.9K → $70.7K (+$14.8K)
0% less ownership
Funds ownership: 0.06% → 0.06% (-0%)
20% less funds holding
Funds holding: 5 → 4 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$14.4K |
| 2 |
VF
Virtu Financial
New York
|
+$13.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$18.1K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$7.91K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.09K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $33K | +$13.7K | +2,089 | +80% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $16.7K | – | – | – |
|
|
HF
3
HRT Financial
New York
| $15K | +$14.4K | +2,190 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $5.94K | +$5.52K | +842 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$18.1K | -3,359 | Closed |
|
|
TSS
6
Two Sigma Securities
New York
| – | -$7.91K | -1,492 | Closed |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| – | -$3.09K | -583 | Closed |
|
BGLC Hedge Fund Activity: Q1 2024 in Review
4 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in BioNexus Gene Lab (BGLC) for Q1 2024, worth a combined $70.7K — up 26% from $55.9K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BGLC and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $14.4K. The largest seller was Citadel Advisors, exiting entirely with an estimated $18.1K sold.
- 4 institutional investors held BioNexus Gene Lab (BGLC) as of Q1 2024, down from 5 in Q4 2023.
- Funds reported $70.7K of BioNexus Gene Lab stock for Q1 2024, up 26% quarter-over-quarter.
- 2 funds opened new BioNexus Gene Lab positions in Q1 2024 and 3 closed out, a net change of -1 holder.
- The largest BioNexus Gene Lab buyer in Q1 2024 was HRT Financial, an estimated $14.4K added.
- The largest BioNexus Gene Lab seller in Q1 2024 was Citadel Advisors, an estimated $18.1K sold.
Based on aggregated 13F filings for Q1 2024.